- Home
- TRVI
as 07-26-2024 4:00pm EST
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 197.2M | IPO Year: | 2019 |
| Target Price: | $8.00 | AVG Volume (30 days): | 327.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $4.00 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Trevi Therapeutics Inc. (TRVI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | TRVI | Chief Scientific Officer | May 29 '24 | Sell | $2.55 | 53,368 | $136,109.75 | 214,433 | SEC Form 4 |
| Delfini Lisa | TRVI | Chief Financial Officer | May 22 '24 | Sell | $2.64 | 4,350 | $11,484.87 | 53,279 | SEC Form 4 |
| GOOD JENNIFER L | TRVI | President & CEO | May 20 '24 | Sell | $2.86 | 25,037 | $71,575.78 | 213,313 | SEC Form 4 |
| GOOD JENNIFER L | TRVI | President & CEO | May 10 '24 | Sell | $2.90 | 4,578 | $13,276.20 | 213,313 | SEC Form 4 |
Latest Trevi Therapeutics Inc. News
TRVI Breaking Stock News: Dive into TRVI Ticker-Specific Updates for Smart Investing
PR Newswire
25 days ago
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Simply Wall St.
a month ago
Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
Insider Monkey
2 months ago
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
PR Newswire
3 months ago
Trevi Therapeutics to Participate in Upcoming Conferences
Thomson Reuters StreetEvents
3 months ago
Q1 2024 Trevi Therapeutics Inc Earnings Call
GuruFocus.com
3 months ago
Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis
PR Newswire
3 months ago
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
PR Newswire
3 months ago
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Compare TRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.